vs
Side-by-side financial comparison of Bausch Health Companies Inc. (BHC) and Workday, Inc. (WDAY). Click either name above to swap in a different company.
Bausch Health Companies Inc. is the larger business by last-quarter revenue ($2.8B vs $2.4B, roughly 1.1× Workday, Inc.). Workday, Inc. runs the higher net margin — 10.4% vs -3.7%, a 14.0% gap on every dollar of revenue. On growth, Workday, Inc. posted the faster year-over-year revenue change (12.6% vs 9.3%). Workday, Inc. produced more free cash flow last quarter ($550.0M vs $403.0M). Over the past eight quarters, Bausch Health Companies Inc.'s revenue compounded faster (14.0% CAGR vs 12.5%).
Bausch Health Companies Inc. is a global, diversified American-Canadian pharmaceutical company. Its global corporate headquarters are located in Laval, Quebec, Canada, and its U.S. headquarters are in Bridgewater, New Jersey. It develops, manufactures and markets a range of pharmaceutical products in gastroenterology, hepatology, neurology, dermatology, dentistry, medical aesthetics, and international pharmaceuticals. Bausch Health manufactures and markets branded pharmaceuticals, generic ph...
Workday, Inc. is a leading global enterprise cloud software provider that develops and distributes human capital management, financial management, and enterprise resource planning solutions. It caters primarily to mid-sized and large organizations across sectors including education, healthcare, finance, and technology, with operations spanning North America, Europe, and Asia Pacific.
BHC vs WDAY — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $2.8B | $2.4B |
| Net Profit | $-103.0M | $252.0M |
| Gross Margin | — | — |
| Operating Margin | 17.0% | 10.6% |
| Net Margin | -3.7% | 10.4% |
| Revenue YoY | 9.3% | 12.6% |
| Net Profit YoY | -205.1% | 30.6% |
| EPS (diluted) | $-0.30 | $0.94 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.8B | $2.4B | ||
| Q3 25 | $2.7B | $2.3B | ||
| Q2 25 | $2.5B | $2.2B | ||
| Q1 25 | $2.3B | $2.2B | ||
| Q4 24 | $2.6B | $2.2B | ||
| Q3 24 | $2.5B | $2.1B | ||
| Q2 24 | $2.4B | $2.0B | ||
| Q1 24 | $2.2B | $1.9B |
| Q4 25 | $-103.0M | $252.0M | ||
| Q3 25 | $179.0M | $228.0M | ||
| Q2 25 | $148.0M | $68.0M | ||
| Q1 25 | $-58.0M | $94.0M | ||
| Q4 24 | $98.0M | $193.0M | ||
| Q3 24 | $-85.0M | $132.0M | ||
| Q2 24 | $10.0M | $107.0M | ||
| Q1 24 | $-64.0M | $1.2B |
| Q4 25 | 17.0% | 10.6% | ||
| Q3 25 | 23.1% | 10.6% | ||
| Q2 25 | 17.5% | 1.7% | ||
| Q1 25 | 12.2% | 3.4% | ||
| Q4 24 | 21.8% | 7.6% | ||
| Q3 24 | 12.7% | 5.3% | ||
| Q2 24 | 16.2% | 3.2% | ||
| Q1 24 | 13.1% | 4.1% |
| Q4 25 | -3.7% | 10.4% | ||
| Q3 25 | 6.7% | 9.7% | ||
| Q2 25 | 5.8% | 3.0% | ||
| Q1 25 | -2.6% | 4.3% | ||
| Q4 24 | 3.8% | 8.9% | ||
| Q3 24 | -3.4% | 6.3% | ||
| Q2 24 | 0.4% | 5.4% | ||
| Q1 24 | -3.0% | 61.8% |
| Q4 25 | $-0.30 | $0.94 | ||
| Q3 25 | $0.48 | $0.84 | ||
| Q2 25 | $0.40 | $0.25 | ||
| Q1 25 | $-0.16 | $0.34 | ||
| Q4 24 | $0.24 | $0.72 | ||
| Q3 24 | $-0.23 | $0.49 | ||
| Q2 24 | $0.03 | $0.40 | ||
| Q1 24 | $-0.17 | $4.48 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.3B | $6.8B |
| Total DebtLower is stronger | $20.8B | — |
| Stockholders' EquityBook value | $-554.0M | $8.9B |
| Total Assets | $26.4B | $17.8B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.3B | $6.8B | ||
| Q3 25 | $1.3B | $8.2B | ||
| Q2 25 | $1.7B | $8.0B | ||
| Q1 25 | $1.1B | $8.0B | ||
| Q4 24 | $1.2B | $7.2B | ||
| Q3 24 | $719.0M | $7.4B | ||
| Q2 24 | $595.0M | $7.2B | ||
| Q1 24 | $733.0M | $7.8B |
| Q4 25 | $20.8B | — | ||
| Q3 25 | $21.0B | — | ||
| Q2 25 | $21.7B | — | ||
| Q1 25 | $21.5B | — | ||
| Q4 24 | $21.6B | — | ||
| Q3 24 | $21.5B | — | ||
| Q2 24 | $21.7B | $3.0B | ||
| Q1 24 | $22.1B | $3.0B |
| Q4 25 | $-554.0M | $8.9B | ||
| Q3 25 | $-565.0M | $9.2B | ||
| Q2 25 | $-764.0M | $8.9B | ||
| Q1 25 | $-1.2B | $9.0B | ||
| Q4 24 | $-1.3B | $8.6B | ||
| Q3 24 | $-1.2B | $8.3B | ||
| Q2 24 | $-1.2B | $8.2B | ||
| Q1 24 | $-1.1B | $8.1B |
| Q4 25 | $26.4B | $17.8B | ||
| Q3 25 | $26.8B | $18.0B | ||
| Q2 25 | $27.3B | $17.2B | ||
| Q1 25 | $26.4B | $18.0B | ||
| Q4 24 | $26.5B | $16.4B | ||
| Q3 24 | $26.5B | $16.2B | ||
| Q2 24 | $26.5B | $15.9B | ||
| Q1 24 | $26.9B | $16.5B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.37× | ||
| Q1 24 | — | 0.37× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $495.0M | $588.0M |
| Free Cash FlowOCF − Capex | $403.0M | $550.0M |
| FCF MarginFCF / Revenue | 14.4% | 22.6% |
| Capex IntensityCapex / Revenue | 3.3% | 1.6% |
| Cash ConversionOCF / Net Profit | — | 2.33× |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | $2.6B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $495.0M | $588.0M | ||
| Q3 25 | $405.0M | $616.0M | ||
| Q2 25 | $289.0M | $457.0M | ||
| Q1 25 | $211.0M | $1.1B | ||
| Q4 24 | $601.0M | $406.0M | ||
| Q3 24 | $405.0M | $571.0M | ||
| Q2 24 | $380.0M | $372.0M | ||
| Q1 24 | $211.0M | $995.6M |
| Q4 25 | $403.0M | $550.0M | ||
| Q3 25 | $314.0M | $588.0M | ||
| Q2 25 | $190.0M | $421.0M | ||
| Q1 25 | $96.0M | $1.0B | ||
| Q4 24 | $495.0M | $359.0M | ||
| Q3 24 | $334.0M | $516.0M | ||
| Q2 24 | $302.0M | $291.0M | ||
| Q1 24 | $129.0M | $947.6M |
| Q4 25 | 14.4% | 22.6% | ||
| Q3 25 | 11.7% | 25.0% | ||
| Q2 25 | 7.5% | 18.8% | ||
| Q1 25 | 4.2% | 46.4% | ||
| Q4 24 | 19.3% | 16.6% | ||
| Q3 24 | 13.3% | 24.7% | ||
| Q2 24 | 12.6% | 14.6% | ||
| Q1 24 | 6.0% | 49.3% |
| Q4 25 | 3.3% | 1.6% | ||
| Q3 25 | 3.4% | 1.2% | ||
| Q2 25 | 3.9% | 1.6% | ||
| Q1 25 | 5.1% | 3.9% | ||
| Q4 24 | 4.1% | 2.2% | ||
| Q3 24 | 2.8% | 2.6% | ||
| Q2 24 | 3.2% | 4.1% | ||
| Q1 24 | 3.8% | 2.5% |
| Q4 25 | — | 2.33× | ||
| Q3 25 | 2.26× | 2.70× | ||
| Q2 25 | 1.95× | 6.72× | ||
| Q1 25 | — | 11.83× | ||
| Q4 24 | 6.13× | 2.10× | ||
| Q3 24 | — | 4.33× | ||
| Q2 24 | 38.00× | 3.48× | ||
| Q1 24 | — | 0.84× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BHC
| Bausch Lomb | $1.4B | 50% |
| Salix Segment | $693.0M | 25% |
| International Rx | $306.0M | 11% |
| Diversified Segment | $255.0M | 9% |
| Solta Medical Segment | $137.0M | 5% |
WDAY
| Subscription Services | $2.2B | 92% |
| Professional Services | $188.0M | 8% |
